Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.61
- Piotroski Score 2.00
- Grade Buy
- Symbol (LXEO)
- Company Lexeo Therapeutics, Inc. Common Stock
- Price $5.99
- Changes Percentage (-9.92%)
- Change -$0.66
- Day Low $5.82
- Day High $6.63
- Year High $22.33
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/09/2024
- Fiscal Year End N/A
- Average Stock Price Target $28.00
- High Stock Price Target $28.00
- Low Stock Price Target $28.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-66,394,000
Income Statement
Quarterly
Annual
Latest News of LXEO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Companies Like Lexeo Therapeutics (NASDAQ:LXEO) Are In A Position To Invest In Growth
While unprofitable companies may collapse due to cash burn, Lexeo Therapeutics (NASDAQ:LXEO) has a healthy cash balance, enough to sustain operations for 3.5 years. Despite revenue challenges, the com...
By Yahoo! Finance | 5 months ago
